Patients with moderate-to-severe T2DM and CKD were treated with insulin and an angiotensin receptor blocker or angiotensin-converting enzyme inhibitor at the maximum dose along with dulaglutide injected once weekly. This evidence concerns the gene INS and chronic kidney disease.